Skip to main content
. 2014 Aug 25;32(28):3096–3102. doi: 10.1200/JCO.2014.56.5853

Fig 4.

Fig 4.

Response duration of patients with follicular lymphoma (A) assigned to re-treatment rituximab (RR; n = 143) or maintenance rituximab (n = 146) and (B) assigned to RR according to first rituximab treatment (n = 143), first rituximab re-treatment (n = 34), and second rituximab re-treatment (n = 8). Zero of four patients responded to third rituximab re-treatment. FU, follow-up.